Treatment with an aromatase inhibitor, either alone or in combination with growth hormone (GH), slowed bone advancement and enhanced adult height in mid-pubertal boys with a short predicted adult ...

[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its ...

Panelists discuss how testing for specific changes in cancer cells, like ESR1 mutations, can help guide treatment choices for ...

A new drug that reduces the risk of breast cancer recurrence has been approved in England. According to an analysis by the International Agency for Research on Cancer (IARC), worldwide one in ...

Balancing estrogen isn’t just about cutting soy—it’s about strategic, science-backed foods that go beyond the basics ...

Women diagnosed with DCIS face a threefold higher risk of breast cancer mortality. Learn the warning signs, treatment options ...

(FierceBiotech) Aromatase inhibitors and recombinant human growth hormone in combination significantly boosted adult height in adolescent boys with idiopathic short stature. (Journal of Clinical ...

It is used in combination with an aromatase inhibitor as a first-line endocrine therapy for postmenopausal women or men or with fulvestrant for patients whose disease has progressed after ...

STAAR Low-Grade Serous Ovarian Cancer Foundation and Not These Ovaries Fund Breakthrough Research at MD Anderson Cancer ...